NCT00199849View on ClinicalTrials.gov

NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 27, 2004

Primary Completion Date

September 11, 2006

Study Completion Date

September 30, 2007

Conditions
Prostate CancerBladder CancerNon-small Cell Lung CancerEsophageal CancerSarcoma
Interventions
BIOLOGICAL

NY-ESO-1 Plasmid DNA Cancer Vaccine

NY-ESO-1 Plasmid DNA Cancer Vaccine administered by particle-mediated epidermal delivery (PMED) at a pressure of 500 psi using the XR-1 Powderject® delivery device.

Trial Locations (2)

10021

New York Presbyterian Hospital, New York

77030

UT MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

New York Presbyterian Hospital

OTHER

collaborator

M.D. Anderson Cancer Center

OTHER

collaborator

Memorial Sloan Kettering Cancer Center

OTHER

lead

Ludwig Institute for Cancer Research

OTHER